OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
Boris Waldman, Jean-Claude Ansquer, David Sullivan, et al.
The Lancet Diabetes & Endocrinology (2018) Vol. 6, Iss. 4, pp. 310-318
Closed Access | Times Cited: 56
Boris Waldman, Jean-Claude Ansquer, David Sullivan, et al.
The Lancet Diabetes & Endocrinology (2018) Vol. 6, Iss. 4, pp. 310-318
Closed Access | Times Cited: 56
Showing 1-25 of 56 citing articles:
Gout
Nicola Dalbeth, Anna L. Gosling, Angelo Gaffo, et al.
The Lancet (2021) Vol. 397, Iss. 10287, pp. 1843-1855
Closed Access | Times Cited: 811
Nicola Dalbeth, Anna L. Gosling, Angelo Gaffo, et al.
The Lancet (2021) Vol. 397, Iss. 10287, pp. 1843-1855
Closed Access | Times Cited: 811
2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis Care & Research (2020) Vol. 72, Iss. 6, pp. 744-760
Open Access | Times Cited: 654
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis Care & Research (2020) Vol. 72, Iss. 6, pp. 744-760
Open Access | Times Cited: 654
2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis & Rheumatology (2020) Vol. 72, Iss. 6, pp. 879-895
Open Access | Times Cited: 553
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis & Rheumatology (2020) Vol. 72, Iss. 6, pp. 879-895
Open Access | Times Cited: 553
Gout
Nicola Dalbeth, Hyon K. Choi, Leo A. B. Joosten, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 480
Nicola Dalbeth, Hyon K. Choi, Leo A. B. Joosten, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 480
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout
Romy Hansildaar, Daisy Vedder, Milad Baniaamam, et al.
The Lancet Rheumatology (2020) Vol. 3, Iss. 1, pp. e58-e70
Open Access | Times Cited: 184
Romy Hansildaar, Daisy Vedder, Milad Baniaamam, et al.
The Lancet Rheumatology (2020) Vol. 3, Iss. 1, pp. e58-e70
Open Access | Times Cited: 184
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care
Hyon K. Choi, Natalie McCormick, Chio Yokose
Nature Reviews Rheumatology (2021) Vol. 18, Iss. 2, pp. 97-111
Closed Access | Times Cited: 86
Hyon K. Choi, Natalie McCormick, Chio Yokose
Nature Reviews Rheumatology (2021) Vol. 18, Iss. 2, pp. 97-111
Closed Access | Times Cited: 86
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
Arrigo F.G. Cicero, Federica Fogacci, Masanari Kuwabara, et al.
Medicina (2021) Vol. 57, Iss. 1, pp. 58-58
Open Access | Times Cited: 79
Arrigo F.G. Cicero, Federica Fogacci, Masanari Kuwabara, et al.
Medicina (2021) Vol. 57, Iss. 1, pp. 58-58
Open Access | Times Cited: 79
2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy
Tristan Pascart, Augustin Latourte, René‐Marc Flipo, et al.
Joint Bone Spine (2020) Vol. 87, Iss. 5, pp. 395-404
Open Access | Times Cited: 68
Tristan Pascart, Augustin Latourte, René‐Marc Flipo, et al.
Joint Bone Spine (2020) Vol. 87, Iss. 5, pp. 395-404
Open Access | Times Cited: 68
How should we manage asymptomatic hyperuricemia?
Gérard Chalès
Joint Bone Spine (2018) Vol. 86, Iss. 4, pp. 437-443
Closed Access | Times Cited: 66
Gérard Chalès
Joint Bone Spine (2018) Vol. 86, Iss. 4, pp. 437-443
Closed Access | Times Cited: 66
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
João Pedro Ferreira, Silvio E. Inzucchi, Michaela Mattheus, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 135-141
Open Access | Times Cited: 50
João Pedro Ferreira, Silvio E. Inzucchi, Michaela Mattheus, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 135-141
Open Access | Times Cited: 50
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
Jingwei Li, Sunil V. Badve, Zien Zhou, et al.
The Lancet Rheumatology (2019) Vol. 1, Iss. 4, pp. e220-e228
Open Access | Times Cited: 49
Jingwei Li, Sunil V. Badve, Zien Zhou, et al.
The Lancet Rheumatology (2019) Vol. 1, Iss. 4, pp. e220-e228
Open Access | Times Cited: 49
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Diana Ferrão, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1584-1591
Open Access | Times Cited: 23
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Diana Ferrão, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1584-1591
Open Access | Times Cited: 23
ZnO Nanocages Decorated with Au@AgAu Yolk–Shell Nanomaterials for SERS-Based Detection of Hyperuricemia
Mei-Chin Lien, I-Hsiu Yeh, Sirimuvva Tadepalli, et al.
ACS Omega (2024) Vol. 9, Iss. 14, pp. 16160-16167
Open Access | Times Cited: 5
Mei-Chin Lien, I-Hsiu Yeh, Sirimuvva Tadepalli, et al.
ACS Omega (2024) Vol. 9, Iss. 14, pp. 16160-16167
Open Access | Times Cited: 5
Benefits and risks of the treatment with fibrates––a comprehensive summary
Bogusław Okopień, Łukasz Bułdak, Aleksandra Bołdys
Expert Review of Clinical Pharmacology (2018) Vol. 11, Iss. 11, pp. 1099-1112
Closed Access | Times Cited: 43
Bogusław Okopień, Łukasz Bułdak, Aleksandra Bołdys
Expert Review of Clinical Pharmacology (2018) Vol. 11, Iss. 11, pp. 1099-1112
Closed Access | Times Cited: 43
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis, Nikolaοs Tentolouris, Natalia G. Vallianou, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 388-388
Open Access | Times Cited: 4
Dimitris Kounatidis, Nikolaοs Tentolouris, Natalia G. Vallianou, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 388-388
Open Access | Times Cited: 4
Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study
Young Youl Hyun, Kyung‐Soo Kim, Sangmo Hong, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4583-4590
Open Access | Times Cited: 4
Young Youl Hyun, Kyung‐Soo Kim, Sangmo Hong, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4583-4590
Open Access | Times Cited: 4
Systemic inflammation response index association with gout in hyperuricemic adults: NHANES 2007–2018
Xiaochan Tian, Guixing Zeng, Junping Wei
Frontiers in Medicine (2025) Vol. 11
Open Access
Xiaochan Tian, Guixing Zeng, Junping Wei
Frontiers in Medicine (2025) Vol. 11
Open Access
Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge
Wenyi Gu, Jiajing Zhao, Yu Xu
Frontiers in Immunology (2025) Vol. 16
Open Access
Wenyi Gu, Jiajing Zhao, Yu Xu
Frontiers in Immunology (2025) Vol. 16
Open Access
Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study
Yuichi Saito, Atsushi Tanaka, Hisako Yoshida, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2324-2324
Open Access | Times Cited: 3
Yuichi Saito, Atsushi Tanaka, Hisako Yoshida, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2324-2324
Open Access | Times Cited: 3
Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
Ruixia Bao, Beibei Chen, Alexander Wang, et al.
Free Radical Biology and Medicine (2024)
Closed Access | Times Cited: 3
Ruixia Bao, Beibei Chen, Alexander Wang, et al.
Free Radical Biology and Medicine (2024)
Closed Access | Times Cited: 3
Effect of fenofibrate on uric acid level in patients with gout
Ju‐Yang Jung, Young Choi, Chang‐Hee Suh, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 26
Ju‐Yang Jung, Young Choi, Chang‐Hee Suh, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 26
The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study
Niki Katsiki, Matina Kouvari, Demosthenes B. Panagiotakos, et al.
Reviews in Cardiovascular Medicine (2021) Vol. 22, Iss. 3, pp. 991-991
Open Access | Times Cited: 19
Niki Katsiki, Matina Kouvari, Demosthenes B. Panagiotakos, et al.
Reviews in Cardiovascular Medicine (2021) Vol. 22, Iss. 3, pp. 991-991
Open Access | Times Cited: 19
Association of Pericardiac Adipose Tissue With Coronary Artery Disease
Mingxuan Li, Lin Qi, Yanglei Li, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 16
Mingxuan Li, Lin Qi, Yanglei Li, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 16
Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis
Jie Zhang, Xiaopeng Ji, Zehua Dong, et al.
Endocrine Journal (2021) Vol. 68, Iss. 7, pp. 829-837
Open Access | Times Cited: 14
Jie Zhang, Xiaopeng Ji, Zehua Dong, et al.
Endocrine Journal (2021) Vol. 68, Iss. 7, pp. 829-837
Open Access | Times Cited: 14
